Abiopharma

🔍 Furuta Milano (Director)

Company: TAKEDA PHARMACEUTICAL CO LTD (TAK)

Report Date: 2026-04-27

Detailed Transactions and Holdings:

• Acquired 7,800 shares of Ordinary Shares (Direct)
  Date: 2026-04-27 | Code: A | equity_swap_involved: 0 | shares_owned_after: 57,900.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 7,814 shares of Tax Obligation Award (Derivative)
  Date: 2026-04-27 | Code: A | Expires: 2026-06-01 | Exercise: 2026-06-01 | equity_swap_involved: 0 | shares_owned_after: 16,619.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: On July 1, 2023, the reporting person was granted an award of restricted stock units (RSUs), which vest in the form of ordinary shares based upon the achievement of the specified performance metrics, including core revenue, core operating profit, and important R&D milestones. On April 27, 2026, the Compensation Committee of the Board of Directors determined the number of RSUs to be awarded based on these performance metrics, which amount is reported above.
• F2: Includes 27,300 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one Ordinary Share. The RSUs vest on the following schedule: June 1, 2026 (16,200 shares), June 1, 2027 (7,100 shares) and June 1, 2028 (4000 shares).
• F3: Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares.